This report aims to provide a comprehensive presentation of the global market for Non-Small Cell Lung Cancer, with and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Small Cell Lung Cancer.
The Non-Small Cell Lung Cancer market size considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Non-Small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Small Cell Lung Cancer manufacturers, new entrants, and industry chain related companies in this market with information for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
The global Non-Small Cell Lung Cancer market size in 2022 is 26948.36 million US dollars, and it is expected to be 67019.07 million US dollars by 2029, with a compound annual growth rate of 13.90% expected in 2023-2029.
MARKET COMPETITIVE LANDSCAPE:
The main players in the Non-Small Cell Lung Cancer market include F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), and Pfizer Inc. (U.S.). The share of the top 3 players in the Non-Small Cell Lung Cancer market is XX%.
REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, in which North America accounted for XX%, Europe accounted for XX% of Non-Small Cell Lung Cancer market, and Asia Pacific accounted for XX%.
SEGMENT OVERVIEW:
The report segments the market by Type and Application. Adenocarcinomas accounted for XX% of Non-Small Cell Lung Cancer market in 2022. Squamous Cell Carcinoma share of XX%.
Alkylating Agents accounted for XX% of the Non-Small Cell Lung Cancer market in 2022. Antimetabolites accounts for XX%.
Chapter Outline
Chapter 1: Introduces the product overview, market scope, economic analysis of global regions, and industry dynamic analysis, and then includes inflation analysis, the impact of the Russo-Ukrainian war on the market, and the global impact of the coronavirus disease (COVID-19).
Chapters 2-4: Segmented the global Non-Small Cell Lung Cancer market by type, application and region. Analyze the revenue of market segments from different perspectives.
Chapters 5-9: Provide North America, Europe, Asia-Pacific, Latin America and Middle East & Africa Non-Small Cell Lung Cancer market country revenue data, and includes PEST Analysis.
Chapter 10: Analysis of the competitive environment of Non-Small Cell Lung Cancer market participants. This mainly includes the revenue and market share of the top players, along with the players” M&A and new entrants and expansion plans.
Chapter 11: Analyzes the main companies in the Non-Small Cell Lung Cancer industry, including their main businesses, products/services, revenue, gross margin, and the latest developments.
Chapters 12-14: Provide detailed Non-Small Cell Lung Cancer market forecast data, broken down by type, application, and region to help understand future growth trends.
Chapter 15: Concludes with an explanation of the data sources and research methods.
Highlights-Regions
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Spain
Nordic
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Egypt
South Africa
UAE
Turkey
Saudi Arabia
Player list
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GSK plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Lilly (U.S.)
Merck & Co., Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin (India)
CLOVIS ONCOLOGY (U.S.)
Johnson & Johnson Private Limited (U.S.)
Types list
Adenocarcinomas
Squamous Cell Carcinoma
Large Cell Carcinomas
Others
Application list
Alkylating Agents
Antimetabolites
EGFR Inhibitors
Mitotic Inhibitors
Multi-kinase Inhibitors
Others
List of Tables and Figures
Figure Non-Small Cell Lung Cancer Picture
Table Product Definition of Non-Small Cell Lung Cancer
Table Economic Analysis of Global Regions
Table Market Trends Analysis
Table Market Drivers Analysis
Table Market Challenges Analysis
Table Market Restraints Analysis
Table Inflation Analysis
Table The Impact of the Russian-Ukrainian War on the Market
Figure 2020 (COVID-19) Impact on Global Economic Growth 2019, 2020, 2021
Figure Population infected by the Covid-19 of Major Countries
Table Global Non-Small Cell Lung Cancer Market Size by Type (2018 VS 2023 VS 2029)
Table Global Non-Small Cell Lung Cancer Revenue by Type (2018-2023)
Table Global Non-Small Cell Lung Cancer Revenue and Share by Type (2018-2023)
Table Global Non-Small Cell Lung Cancer Market Size by Application (2018 VS 2023 VS 2029)
Table Global Non-Small Cell Lung Cancer Revenue by Application (2018-2023)
Table Global Non-Small Cell Lung Cancer Revenue Share by Application (2018-2023)
Figure Global Non-Small Cell Lung Cancer Revenue Market Size Growth (2018-2023)
Table Non-Small Cell Lung Cancer Market Size by Regions: 2018 VS 2023 VS 2029
Table Non-Small Cell Lung Cancer Revenue Market Size by Regions (2018-2023)
Table Non-Small Cell Lung Cancer Revenue and Share by Regions (2018-2023)
Figure North America Non-Small Cell Lung Cancer Market Size (2018-2023)
Figure Europe Non-Small Cell Lung Cancer Market Size (2018-2023)
Figure Asia-Pacific Non-Small Cell Lung Cancer Market Size (2018-2023)
Figure Latin America Non-Small Cell Lung Cancer Market Size (2018-2023)
Figure Middle East & Africa Non-Small Cell Lung Cancer Market Size (2018-2023)
Table North America Non-Small Cell Lung Cancer Revenue by Countries (2018-2023)
Table North America Non-Small Cell Lung Cancer Revenue and Share by Countries (2018-2023)
Table North America PEST Analysis
Figure United States Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Canada Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Canada Non-Small Cell Lung Cancer Sales and Growth (2018-2023)
Table Asia-Pacific Non-Small Cell Lung Cancer Revenue by Countries (2018-2023)
Table Asia-Pacific Non-Small Cell Lung Cancer Revenue and Share by Countries (2018-2023)
Table Asia-Pacific PEST Analysis
Figure China Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Japan Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Korea Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Southeast Asia Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure India Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Australia Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Table Europe Non-Small Cell Lung Cancer Revenue by Countries (2018-2023)
Table Europe Non-Small Cell Lung Cancer Revenue and Share by Countries (2018-2023)
Table Europe PEST Analysis
Figure Germany Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure France Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure UK Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Italy Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Russia Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Spain Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Nordic Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Table Latin America Non-Small Cell Lung Cancer Revenue by Countries (2018-2023)
Table Latin America Non-Small Cell Lung Cancer Revenue and Share by Countries (2018-2023)
Table Latin America PEST Analysis
Figure Brazil Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Argentina Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Mexico Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Table Middle East & Africa Non-Small Cell Lung Cancer Revenue by Countries (2018-2023)
Table Middle East & Africa Non-Small Cell Lung Cancer Revenue and Share by Countries (2018-2023)
Table Middle East & Africa PEST Analysis
Figure Egypt Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure South Africa Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure UAE Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Turkey Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Figure Saudi Arabia Non-Small Cell Lung Cancer Revenue and Growth (2018-2023)
Table Global Non-Small Cell Lung Cancer Revenue by Players (2018-2023)
Table Global Non-Small Cell Lung Cancer Revenue Market Share by Players (2018-2023)
Figure Global Top 3 Companies Revenue Share in 2022
Figure Global Top 6 Companies Revenue Share in 2022
Table Global Non-Small Cell Lung Cancer Players Market Concentration Ratio (CR5) (2018-2023)
Table Non-Small Cell Lung Cancer Players Head Office, Business Provided
Table Mergers & Acquisitions
Table New Entrants and Expansion Plans
Table F. Hoffmann-La Roche Ltd. (Switzerland) Profile
Table Product Overview
Table F. Hoffmann-La Roche Ltd. (Switzerland) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure F. Hoffmann-La Roche Ltd. (Switzerland) Revenue and Growth Rate
Figure F. Hoffmann-La Roche Ltd. (Switzerland) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Mylan N.V. (U.S.) Profile
Table Product Overview
Table Mylan N.V. (U.S.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Mylan N.V. (U.S.) Revenue and Growth Rate
Figure Mylan N.V. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Teva Pharmaceutical Industries Ltd. (Israel) Profile
Table Product Overview
Table Teva Pharmaceutical Industries Ltd. (Israel) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Teva Pharmaceutical Industries Ltd. (Israel) Revenue and Growth Rate
Figure Teva Pharmaceutical Industries Ltd. (Israel) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Sanofi (France) Profile
Table Product Overview
Table Sanofi (France) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Sanofi (France) Revenue and Growth Rate
Figure Sanofi (France) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Pfizer Inc. (U.S.) Profile
Table Product Overview
Table Pfizer Inc. (U.S.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Pfizer Inc. (U.S.) Revenue and Growth Rate
Figure Pfizer Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table GSK plc (U.K.) Profile
Table Product Overview
Table GSK plc (U.K.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure GSK plc (U.K.) Revenue and Growth Rate
Figure GSK plc (U.K.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Novartis AG (Switzerland) Profile
Table Product Overview
Table Novartis AG (Switzerland) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Novartis AG (Switzerland) Revenue and Growth Rate
Figure Novartis AG (Switzerland) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Bayer AG (Germany) Profile
Table Product Overview
Table Bayer AG (Germany) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Bayer AG (Germany) Revenue and Growth Rate
Figure Bayer AG (Germany) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Lilly (U.S.) Profile
Table Product Overview
Table Lilly (U.S.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Lilly (U.S.) Revenue and Growth Rate
Figure Lilly (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Merck & Co., Inc. (U.S.) Profile
Table Product Overview
Table Merck & Co., Inc. (U.S.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Merck & Co., Inc. (U.S.) Revenue and Growth Rate
Figure Merck & Co., Inc. (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Sun Pharmaceutical Industries Ltd. (India) Profile
Table Product Overview
Table Sun Pharmaceutical Industries Ltd. (India) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Sun Pharmaceutical Industries Ltd. (India) Revenue and Growth Rate
Figure Sun Pharmaceutical Industries Ltd. (India) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Aurobindo Pharma (India) Profile
Table Product Overview
Table Aurobindo Pharma (India) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Aurobindo Pharma (India) Revenue and Growth Rate
Figure Aurobindo Pharma (India) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Lupin (India) Profile
Table Product Overview
Table Lupin (India) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Lupin (India) Revenue and Growth Rate
Figure Lupin (India) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table CLOVIS ONCOLOGY (U.S.) Profile
Table Product Overview
Table CLOVIS ONCOLOGY (U.S.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure CLOVIS ONCOLOGY (U.S.) Revenue and Growth Rate
Figure CLOVIS ONCOLOGY (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Johnson & Johnson Private Limited (U.S.) Profile
Table Product Overview
Table Johnson & Johnson Private Limited (U.S.) Non-Small Cell Lung Cancer Revenue, Gross and Gross Margin (2018-2023)
Figure Johnson & Johnson Private Limited (U.S.) Revenue and Growth Rate
Figure Johnson & Johnson Private Limited (U.S.) Revenue Market Share 2017-2022
Table Business Overview
Table Recent Developments and Plans
Table Global Non-Small Cell Lung Cancer Revenue Forecast by Type (2023-2029)
Table Global Non-Small Cell Lung Cancer Revenue and Share Forecast by Type (2023-2029)
Table Global Non-Small Cell Lung Cancer Revenue by Application (2023-2029)
Table Global Non-Small Cell Lung Cancer Revenue and Share by Application (2023-2029)
Figure Global Non-Small Cell Lung Cancer Revenue Forecast Market Size (2023-2029)
Table Non-Small Cell Lung Cancer Revenue Forecast by Regions (2023-2029)
Table Non-Small Cell Lung Cancer Revenue and Share Forecast by Regions (2023-2029)
Figure North America Non-Small Cell Lung Cancer Revenue Forecast Market Size (2023-2029)
Figure Europe Non-Small Cell Lung Cancer Revenue Forecast Market Size (2023-2029)
Figure Asia-Pacific Non-Small Cell Lung Cancer Revenue Forecast Market Size (2023-2029)
Figure Latin America Non-Small Cell Lung Cancer Revenue Forecast Market Size (2023-2029)
Figure Middle East & Africa Non-Small Cell Lung Cancer Revenue Forecast Market Size (2023-2029)
Table Research Process
Figure Bottom-up and Top-down Approaches for This Report
